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1. Introduction 
Despite impressive studies of superoxide dismutases 
(SOD), the actual extent of 02- production in living 
cells remains unknown [ 1,2]. Exceptions are granulo- 
cytes and alveolar macrophages which release super- 
oxide anions during phagocytosis [3]. 
Catalase was first described in 18 12 [4]; never- 
theless, it is still debatable whether this enzyme is 
essential for life in mammalian tissues, In the liver of 
the anaesthetized rat that hydrogen peroxide is 
produced and binds to catalase [S]; however, the 
source of this HzOz is undetermined. 
We have examined the presence of the catalase- 
peroxide complex (compound I) in the liver of 
unanaesthetized guinea pigs, by means of the irrevers- 
ible inhibition of catalase by 3-amino-1,2,4triazole 
(AT) administration in vivo. This inhibitor only binds 
to compound I and not to free catalase [6]. Further 
to this, the source of hydrogen peroxide was studied 
by administration of inhibitors of several peroxide 
producing oxidases. The results indicate that peroxi- 
somal as well as cytoplasmic catalase is active in vivo, 
and that in unstimulated and physiological conditions 
superoxide dismutase is providing part of the hydrogen 
peroxide. Preliminary results have been reported [7]. 
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2. Material and methods 
Male DHPL guinea pigs (300-400 g) had free 
access to food and water during the experiment. 
AT 1 g/kg body wt was injected intraperitoneally 
without anaesthesia, and the animals were sacrificed 
after 0.5, 1,2,3,4 and 5 h. Catalase activity was 
assayed in total liver homogenate with the titaniumoxy- 
sulfate method [8]. 
The following enzyme inhibitors were administered 
by a single injection 1 h prior to AT administration: 
diethyldithiocarbamate (1.2-l 5 g/kg intraperitone- 
ally), an inhibitor of superoxide dismutase [9-l I]; 
oxonic acid (250 mg/kg i.p.) [12] and trichloro- 
purine (50 mg/kg s.c.) [ 131, both inhibitors of urate 
oxidase; allopurinol(150 mg/kg s.c.), an inhibitor of 
xanthine oxidase [14,15]; iproniazide (50 mg/kg i.p.), 
an inhibitor of monoamine oxidase [ 161; atebrine 
(100 or 200 mg/kg i.p.), an inhibitor of D-amino acid 
oxidase [ 171 and glycolate oxidase [ 181; metyrapone 
(150 mg/kg s.c.), an inhibitor of the cytochrome 
P450dependent monooxygenase system [ 19,201. 
3. Results 
After AT administration, liver catalase activity 
declines exponentially, reaching 1.6% after 5 h (fig.1). 
When diethyldithiocarbamate (DDC), an inhibitor 
of superoxide dismutase, is given prior to AT, catalase 
activity after 4 h is 19%, showing that part of the 
enzyme is in the free form (table 1). 
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Fig.1. Catalase activity in total liver homogenate after 
administration of AT: (*) activity expressed in units/g fresh 
liver; (A) log of these values. 
4. Discussion 
The inhibition by AT shows that most of the 
hepatic catalase is present as compound I in physiol- 
ogical conditions; in the rat similar conclusions were 
reached [21] and in the anaesthetized animal [5]. 
The presence of sufficient amounts of HzOz is not a 
mere result of the enzyme inhibition, because the AT 
effect is roughly proportional to the amount of active 
catalase (fig.1). 
Table 1 





261.5 + 1.8 
100 
AT (4 h) AT + DDC (4 h) 
6.9 + 1.8 50.4 i 11.9 
2.6 18.8 
a Means f SEM; the difference between AT and DDC is sig- 
nificant 0.01 < p < 0.02 
Unlike the situation in the rat, between 56% and 
87% of the hepatic catalase in the male guinea pig is 
localized in the cytosol, the remainder being peroxi- 
somal enzyme. This was calculated from microspec- 
trophotometric data after diaminobenzidine staining 
for catalase [22]. As a consequence these results 
prove for the first time that cytoplasmic catalase is 
provided with substrate under physiological condi- 
tions. 
Inhibition of SOD is accompanied by a substantial 
decrease of hydrogen peroxide production, as shown 
by an increase in free active catalase. Although DDC 
also inhibits 2 other enzymes, glutathione (GSH) 
peroxidase [23] and aldehyde dehydrogenase [24], 
this cannot be the cause of the increased catalase 
activity. Catalase itself is unaffected by DDC 
[10,23,25]. 
The importance of H202 production by hepatic 
SOD is probably underestimated because inhibition 
by DDC is only 7 I % [9], and also because part of 
the peroxide possibly reacts with GSH peroxidase 
and thus escapes detection. The latter enzyme appar- 
ently is not implicated in destruction of endogenous 
HzOz in isolated rat hepatocytes [26]. 
The efficient cooperation between catalase and 
SOD must be facilitated by the localisation of both 
enzymes in the cytosolic compartment of the paren- 
chymal cell, A small amount of SOD is also found in 
the mitochondria, but this belongs partly to the 
Mn-type SODwhichis not affected by DDC [27-3 11. 
The activities of catalase and SOD have been com- 
pared in vitro; the results were not in favour of the 
existence of cooperation 132-371. 
The advantage for the cell of such cooperation can 
be assumed on the basis of in vitro experiments: 
HzOz inactivates SOD [38,39]; co-immobilization of 
catalase and glucose oxidase protects the latter from 
deactivation by its own reaction product, HzOz [40]; 
co-immobilization of catalase, SOD and xanthine 
oxidase similarly prolongs the activity of the latter 
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enzyme [41]. However, the activity of catalase leads 
to conservation of 02, a function that should be 
particularly valuable under conditions of ischemia. 
The lack of any demonstrable effect on catalase 
after administration of inhibitors of other oxidases, 
does not necessarily mean that those are inactive in 
the living cell. The degree of inhibition by some of 
these substances has been tested only in vitro (atebrine 
[ 17,181; trichloropurine [ 131; metyrapone [19,20]). 
Inhibition of cytochrome P450 by metyrapone is 
<50% if animals were not pretreated with pheno- 
barbital [ 19,201. The effect of oxonic acid on urate 
oxidase attains its maximum (50% inhibition) after 
30 min and then levels off [42]. Finally, HzOz can 
also be metabolized by GSH peroxidase. This might 
well explain the negative result during inhibition of 
monoamine oxidase, an enzyme that is localized in 
the mitochondria, as is GSH peroxidase. In perfused 
rat liver an increase in GSH oxidation was demon- 
strated during perfusion of an exogenous amine; 
there was no effect on catalase [43 1. 
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